<p>泰瓦製藥（Teva Pharmaceutical Industries，紐約證券交易所代碼：TEVA - 獲取免費報告）在週六向投資者發佈的報告中，被華爾街 Zen 的股票分析師將評級從 “強烈買入” 下調至 “買入”。</p>
<ul>
<li>MarketBeat 週報 – 02/03 - 02/07</li>
</ul>
<p>其他一些股票分析師最近也對 TEVA 發佈了報告。加拿大豐業銀行在 12 月 5 日（星期五）發佈的報告中開始覆蓋泰瓦製藥的股票。他們給予該股票 “行業跑贏大盤” 的評級，並設定了 35.00 美元的目標價。美國銀行在週二將泰瓦製藥的目標價從 29.00 美元上調至 32.00 美元，並在研究報告中給予該股票 “買入” 評級。巴克萊在週二發佈的研究報告中開始覆蓋泰瓦製藥的股票。他們為該公司設定了 “增持” 評級和 35.00 美元的目標價。瑞銀集團在 9 月 24 日（星期三）將泰瓦製藥的目標價從 23.00 美元上調至 26.00 美元，並給予該股票 “買入” 評級。最後，Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對泰瓦製藥的 “賣出（d-）” 評級。三位投資分析師對該股票給予了強烈買入評級，六位給予了買入評級，一位則給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “買入”，共識目標價為 30.25 美元。</p>
<p><strong>查看我們最新的 TEVA 股票分析</strong></p>
<h2>泰瓦製藥股價下跌 1.3%</h2>
<ul>
<li>泰瓦製藥：為什麼這家仿製藥巨頭現在是一個明智的買入選擇</li>
</ul>
<p>泰瓦製藥的股票在週五開盤價為 29.80 美元。該公司的 50 日簡單移動平均為 23.43 美元，200 日簡單移動平均為 19.60 美元。公司市值為 341.8 億美元，市盈率為 49.67，市盈增長比率為 1.79，貝塔值為 0.67。泰瓦製藥的 52 周低點為 12.47 美元，52 周高點為 30.20 美元。公司的速動比率為 0.82，流動比率為 1.11，債務與股本比率為 2.31。</p>
<h2>泰瓦製藥的內部活動</h2>
<p>在相關消息中，董事羅伯託·米尼奧內於 11 月 6 日（星期四）出售了 20 萬股公司的股票。該股票以平均價格 24.11 美元出售，總價值為 4,822,000.00 美元。交易後，該董事直接持有 495,000 股公司股票，價值約為 11,934,450 美元。此次交易使其持股減少了 28.78%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。此外，內部人士馬克·薩巴格於 12 月 9 日（星期二）出售了 216,892 股公司的股票。該股票以平均價格 28.73 美元出售，總價值為 6,231,307.16 美元。交易完成後，內部人士持有 52,828 股公司的股票，價值為 1,517,748.44 美元。此次交易使其持股減少了 80.41%。該銷售的 SEC 文件提供了更多信息。在過去 90 天內，內部人士已出售 532,360 股公司股票，價值為 14,364,929 美元。公司內部人士持有 0.49% 的股票。</p>
<h2>對泰瓦製藥的對沖基金看法</h2>
<ul>
<li>2025 年準備上漲的兩隻仿製藥股票</li>
</ul>
<p>機構投資者最近買入和賣出了該股票的股份。Cromwell Holdings LLC 在第三季度將其在泰瓦製藥的持股增加了 40.3%。Cromwell Holdings LLC 現在擁有 2,191 股公司股票，價值 44,000 美元，此前在上個季度又購買了 629 股。Advisors Asset Management Inc.在第二季度購買了泰瓦製藥的新股份，價值約為 41,000 美元。羅斯柴爾德投資公司在第三季度將其在泰瓦製藥的持股增加了 97.0%。羅斯柴爾德投資公司現在擁有 2,738 股公司股票，價值 55,000 美元，此前在上個季度又收購了 1,348 股。JFS Wealth Advisors LLC 在第三季度將其在泰瓦製藥的持股增加了 257.1%。JFS Wealth Advisors LLC 現在擁有 2,778 股公司股票，價值 56,000 美元，此前在上個季度又收購了 2,000 股。最後，LRI Investments LLC 在第三季度將其在泰瓦製藥的持股增加了 246.0%。LRI Investments LLC 現在擁有 2,813 股公司股票，價值 57,000 美元，此前在上個季度又購買了 2,000 股。54.05% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>泰瓦製藥公司簡介</h2>
<p>（獲取免費報告）</p>
<p>泰瓦製藥有限公司在北美、歐洲、以色列及國際市場開發、生產、營銷和分銷仿製藥、專科藥物和生物製藥產品。它提供各種劑型的仿製藥，如片劑、膠囊、注射劑、吸入劑、液體、透皮貼劑、軟膏和乳膏；無菌產品、激素、高效藥物和細胞毒性物質的注射劑和固體劑型；以及帶有醫療設備的仿製產品和組合產品。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過泰瓦製藥</li>
<li>股息捕捉策略：你需要知道的事項</li>
<li>Synopsys 因 Ansys 整合推動增長而看漲</li>
<li>內部購買解析：投資者需要知道的事項</li>
<li>你能給自己最好的節日禮物是什麼？好市多股票</li>
<li>投資優先股與普通股的區別</li>
<li>為什麼 Zscaler 股票在經歷 30% 的拋售後可能準備反彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在梯瓦製藥嗎？</h2>
<p>在考慮梯瓦製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而梯瓦製藥並不在名單上。</p>
<p>雖然梯瓦製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

梯瓦制藥

<p>華爾街禪在週六的一份報告中將梯瓦製藥的評級從 “強力買入” 下調至 “買入”</p>

<p>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Saturday.</p>
<div class="lb-trans"><p>泰瓦製藥（Teva Pharmaceutical Industries，紐約證券交易所代碼：TEVA - 獲取免費報告）在週六向投資者發佈的報告中，被華爾街 Zen 的股票分析師將評級從 “強烈買入” 下調至 “買入”。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 02/03 - 02/07</li>
</ul>
</div><p>A number of other equities analysts also recently issued reports on TEVA. Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a &#34;sector outperform&#34; rating and a $35.00 price objective on the stock. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday. They set an &#34;overweight&#34; rating and a $35.00 price objective for the company. UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 24th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of &#34;Buy&#34; and a consensus price target of $30.25.</p>
<div class="lb-trans"><p>其他一些股票分析師最近也對 TEVA 發佈了報告。加拿大豐業銀行在 12 月 5 日（星期五）發佈的報告中開始覆蓋泰瓦製藥的股票。他們給予該股票 “行業跑贏大盤” 的評級，並設定了 35.00 美元的目標價。美國銀行在週二將泰瓦製藥的目標價從 29.00 美元上調至 32.00 美元，並在研究報告中給予該股票 “買入” 評級。巴克萊在週二發佈的研究報告中開始覆蓋泰瓦製藥的股票。他們為該公司設定了 “增持” 評級和 35.00 美元的目標價。瑞銀集團在 9 月 24 日（星期三）將泰瓦製藥的目標價從 23.00 美元上調至 26.00 美元，並給予該股票 “買入” 評級。最後，Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對泰瓦製藥的 “賣出（d-）” 評級。三位投資分析師對該股票給予了強烈買入評級，六位給予了買入評級，一位則給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “買入”，共識目標價為 30.25 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on TEVA</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 TEVA 股票分析</strong></p>
</div><h2>Teva Pharmaceutical Industries Trading Down 1.3%</h2>
<div class="lb-trans"><h2>泰瓦製藥股價下跌 1.3%</h2>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>泰瓦製藥：為什麼這家仿製藥巨頭現在是一個明智的買入選擇</li>
</ul>
</div><p>Teva Pharmaceutical Industries stock opened at $29.80 on Friday. The business has a 50-day simple moving average of $23.43 and a two-hundred day simple moving average of $19.60. The company has a market cap of $34.18 billion, a P/E ratio of 49.67, a P/E/G ratio of 1.79 and a beta of 0.67. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $30.20. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.</p>
<div class="lb-trans"><p>泰瓦製藥的股票在週五開盤價為 29.80 美元。該公司的 50 日簡單移動平均為 23.43 美元，200 日簡單移動平均為 19.60 美元。公司市值為 341.8 億美元，市盈率為 49.67，市盈增長比率為 1.79，貝塔值為 0.67。泰瓦製藥的 52 周低點為 12.47 美元，52 周高點為 30.20 美元。公司的速動比率為 0.82，流動比率為 1.11，債務與股本比率為 2.31。</p>
</div><h2>Insider Activity at Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>泰瓦製藥的內部活動</h2>
</div><p>In related news, Director Roberto Mignone sold 200,000 shares of the business's stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company's stock, valued at approximately $11,934,450. The trade was a 28.78% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider Mark Sabag sold 216,892 shares of the company's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares of the company's stock, valued at $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 532,360 shares of company stock valued at $14,364,929. 0.49% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事羅伯託·米尼奧內於 11 月 6 日（星期四）出售了 20 萬股公司的股票。該股票以平均價格 24.11 美元出售，總價值為 4,822,000.00 美元。交易後，該董事直接持有 495,000 股公司股票，價值約為 11,934,450 美元。此次交易使其持股減少了 28.78%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。此外，內部人士馬克·薩巴格於 12 月 9 日（星期二）出售了 216,892 股公司的股票。該股票以平均價格 28.73 美元出售，總價值為 6,231,307.16 美元。交易完成後，內部人士持有 52,828 股公司的股票，價值為 1,517,748.44 美元。此次交易使其持股減少了 80.41%。該銷售的 SEC 文件提供了更多信息。在過去 90 天內，內部人士已出售 532,360 股公司股票，價值為 14,364,929 美元。公司內部人士持有 0.49% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>對泰瓦製藥的對沖基金看法</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年準備上漲的兩隻仿製藥股票</li>
</ul>
</div><p>Institutional investors have recently bought and sold shares of the stock. Cromwell Holdings LLC lifted its position in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock worth $44,000 after buying an additional 629 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $41,000. Rothschild Investment LLC boosted its position in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock valued at $55,000 after acquiring an additional 1,348 shares during the last quarter. JFS Wealth Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company's stock valued at $56,000 after acquiring an additional 2,000 shares during the last quarter. Finally, LRI Investments LLC grew its holdings in shares of Teva Pharmaceutical Industries by 246.0% in the third quarter. LRI Investments LLC now owns 2,813 shares of the company's stock valued at $57,000 after purchasing an additional 2,000 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該股票的股份。Cromwell Holdings LLC 在第三季度將其在泰瓦製藥的持股增加了 40.3%。Cromwell Holdings LLC 現在擁有 2,191 股公司股票，價值 44,000 美元，此前在上個季度又購買了 629 股。Advisors Asset Management Inc.在第二季度購買了泰瓦製藥的新股份，價值約為 41,000 美元。羅斯柴爾德投資公司在第三季度將其在泰瓦製藥的持股增加了 97.0%。羅斯柴爾德投資公司現在擁有 2,738 股公司股票，價值 55,000 美元，此前在上個季度又收購了 1,348 股。JFS Wealth Advisors LLC 在第三季度將其在泰瓦製藥的持股增加了 257.1%。JFS Wealth Advisors LLC 現在擁有 2,778 股公司股票，價值 56,000 美元，此前在上個季度又收購了 2,000 股。最後，LRI Investments LLC 在第三季度將其在泰瓦製藥的持股增加了 246.0%。LRI Investments LLC 現在擁有 2,813 股公司股票，價值 57,000 美元，此前在上個季度又購買了 2,000 股。54.05% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Teva Pharmaceutical Industries Company Profile</h2>
<div class="lb-trans"><h2>泰瓦製藥公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.</p>
<div class="lb-trans"><p>泰瓦製藥有限公司在北美、歐洲、以色列及國際市場開發、生產、營銷和分銷仿製藥、專科藥物和生物製藥產品。它提供各種劑型的仿製藥，如片劑、膠囊、注射劑、吸入劑、液體、透皮貼劑、軟膏和乳膏；無菌產品、激素、高效藥物和細胞毒性物質的注射劑和固體劑型；以及帶有醫療設備的仿製產品和組合產品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>The Best Holiday Present You Can Give Yourself? Costco Stock</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過泰瓦製藥</li>
<li>股息捕捉策略：你需要知道的事項</li>
<li>Synopsys 因 Ansys 整合推動增長而看漲</li>
<li>內部購買解析：投資者需要知道的事項</li>
<li>你能給自己最好的節日禮物是什麼？好市多股票</li>
<li>投資優先股與普通股的區別</li>
<li>為什麼 Zscaler 股票在經歷 30% 的拋售後可能準備反彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=TEVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在梯瓦製藥嗎？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮梯瓦製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而梯瓦製藥並不在名單上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然梯瓦製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

梯瓦製藥（NYSE:TEVA）被華爾街 Zen 下調評級至買入